Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474.


A recent phase 1 trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 led to the death of one volunteer and produced mild-to-severe neurological symptoms in four others. Although the cause of the clinical neurotoxicity is unknown, it has been postulated, given the clinical safety profile of other tested FAAH inhibitors, that off-target… (More)
DOI: 10.1126/science.aaf7497